Bristol-Myers shareholders approve drugmaker's $74 billion deal with Celgene

Article Link: Bristol-Myers shareholders approve drugmaker’s billion deal with Celgene

The deal, announced in January, was a hard sell to Bristol shareholders from the start. The approval concludes a tumultuous period for Bristol, which saw pushback from institutional investors.

Source: CNN Investing